

Science that transforms

CELLS

into

HOPE

Center for Development and Production
of CAR-T Cell Therapies

Strategies for Advanced Therapies




TREATMENT

Innovative cell therapy for leukemias and lymphomas, focusing on refractory patients



ACCESS

Latin America's first public CAR-T production, 100% free through the national health system



SOVEREIGNTY

Aligned with Brazil's Health Industrial Complex (CEIS) to secure scientific autonomy



AUTONOMY

Full mastery of the domestic production chain as the sole technology holder in Latin America



ECONOMY

Drastic cost reduction for the public health system, expanding oncological care capacity



COOPERATION

Positioning Fiocruz as a regional hub for production and technology transfer in Latin America

CURRENT COST OF CAR-T CELL THERAPY

**U\$350
thousand**

per dose/
patient (imported)

**U\$700
million**

Total predict cost
(for 2,000 doses)

PREDICTED COST FOR THE PUBLIC HEALTH SYSTEM WITH THE NEW STRATEGY

**U\$35
thousand**

per dose/patient
(10% of current cost,
with local Fiocruz
production)*

**U\$70
million**

Total predicted cost
(for 2,000 doses)

Savings of
**\$630
million**

90% cost reduction
per patient

*Costs to be confirmed as technology transfer progresses



Technology Base

Lentiviral vectors:

Used to transport and integrate the CAR receptor gene into the patient's defense cells (T lymphocytes)



Local Production

Direct Impact:

Drastic cost reduction and treatment sustainability through local manufacturing at Bio-Manguinhos innovative facility



National Sovereignty

Domestic Production:

Full mastery of the production chain, creating Latin America's first public CAR-T initiative, aligned with Brazil's Health Industrial Complex (CEIS)

Point-of-care production model for CAR-T

The Decentralized Model enables capillary distribution across centers nationwide: a national strategy that begins with the Fiocruz – INCA partnership, but has the potential to expand national cell therapy manufacturing capacity.





HOSPITAL A




HOSPITAL B



**More patients
treated across
Brazil**

CAR-T Cell Therapy for Cancer: How it works in 5 steps



Partners

Technology transfer:
Caring Cross

Clinical study:
INCA

TIMELINE

Past

- Signing of the Caring Cross collaboration agreement
- Approval of engineering documents and factory acceptance testing (FAT)
- Physical installation of the modular unit
- Conducting technical training

Present

- Submission of the phase I and II clinical protocol*
- Obtaining the CTO

Future

- Nationalization of the supply chain
- Supply and cooperation hub in Latin America

*leukemias and lymphomas

Thank You!

business.development@bio.fiocruz.br



MINISTÉRIO DA
SAÚDE

